EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues

Maria Paola Martelli, Gabriella Sozzi, Luis Hernandez, Valentina Pettirossi, Alba Navarro, Davide Conte, Patrizia Gasparini, Federica Perrone, Piergiorgio Modena, Ugo Pastorino, Antonino Carbone, Alessandra Fabbri, Angelo Sidoni, Shigeo Nakamura, Marcello Gambacorta, Pedro Luis Fernandez, Jose Ramirez, John K. C. Chan, Walter Franco Grigioni, Elias CampoStefano A. Pileri, Brunangelo Falini*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

294 Citations (Scopus)


A fusion gene, enchinoderm microtubule associated protein like 4 - anaplastic lymphoma kinase (EML4-ALK), with transforming activity has recently been identified in a subset of non-small cell lung cancer (NSCLC), but its pathogenetic, diagnostic, and therapeutic roles remain unclear. Both frequency and type of EML4-ALK transcripts were investigated by reverse transcription PCR in 120 frozen NSCLC specimens from Italy and Spain; non-neoplastic lung tissues taken far from the tumor were used as controls. in cases carrying the fusion transcript, we determined EML4-ALK gene and protein levels using fluorescence in situ hybridization, Western blotting, and immunoprecipitation. We also analyzed ALK protein levels in paraffin samples from 662 NSCLC specimens, including the 120 cases investigated in the molecular studies. EML4-ALK transcripts (variants I and 3) were detected in 9 of 120 NSCLC samples but were not specific for NSCLC since they were also found in non-cancerous lung tissues taken far from the tumor. Notably, no transcripts were detected in matching tumor samples from these patients. Fluorescence in situ hybridization analysis of cases expressing EML4-ALK transcripts showed that only a minority of cells harbored the EML4-ALK gene. None of these cases was found to express the EML4-ALK protein as examined by immunohistochemistry, Western blotting, and immunoprecipitation. The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for NSCLC. Our results show therefore that the causal role and value of EML4-ALK as a therapeutic target remain to be defined. (Am J Pathol 2009, 174:661-670; DOI: 10.2353/ajpath.2009.080755)

Original languageEnglish
Pages (from-to)661-670
Number of pages10
JournalAm. J. Pathol.
Issue number2
Publication statusPublished - Feb 2009


  • NPM
  • TPM3-ALK


Dive into the research topics of 'EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues'. Together they form a unique fingerprint.

Cite this